A comparison of dabigatran with warfarin for stroke prevention in atrial fibrillation in an Asian population
LB Yap, DTS Eng, L Sivalingam… - Clinical and Applied …, 2016 - journals.sagepub.com
Background: The Asian population with atrial fibrillation (AF) have a higher risk of stroke
than the caucasian population and a higher risk of intracranial bleeding when …
than the caucasian population and a higher risk of intracranial bleeding when …
[HTML][HTML] Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting
Y Zheng, SV Sorensen, AK Gonschior, H Noack… - Clinical …, 2014 - Elsevier
Purpose Three new oral anticoagulants (NOACs) have recently become available in the
United Kingdom as an alternative to warfarin in the prevention of stroke and systemic …
United Kingdom as an alternative to warfarin in the prevention of stroke and systemic …
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE …
Objectives: The goal of this study was to analyze the impact of dabigatran plasma
concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic …
concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic …
Dabigatran versus warfarin for the prevention of stroke in Chinese patients with nonvalvular atrial fibrillation: Chinese subpopulation analysis of RE-LY
X Gao, YM Yang, J Zhu, Y Dai, HQ Tan - … xin xue Guan Bing za zhi, 2016 - europepmc.org
Objective: This analysis was performed to evaluate the efficacy in stroke prevention and
safety of dabigatran in Chinese nonvalvular atrial fibrillation (NVAF) patients enrolled in RE …
safety of dabigatran in Chinese nonvalvular atrial fibrillation (NVAF) patients enrolled in RE …
Indirect treatment comparison and economic evaluation of novel oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in the Netherlands
Objectives Management with vitamin K antagonists (VKAs) has been an effective and cost-
effective strategy for stroke prevention in atrial fibrillation (AF) but is associated with …
effective strategy for stroke prevention in atrial fibrillation (AF) but is associated with …
Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial
JJ DiNicolantonio - Expert Opinion on Pharmacotherapy, 2012 - Taylor & Francis
Introduction: In the Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY)
trial, dabigatran 150 mg was shown to be superior to warfarin for the prevention of stroke or …
trial, dabigatran 150 mg was shown to be superior to warfarin for the prevention of stroke or …
Effects of dabigatran according to age in atrial fibrillation
MN Lauw, JW Eikelboom, M Coppens, L Wallentin… - Heart, 2017 - heart.bmj.com
Objective The prevalence of atrial fibrillation (AF) and the risk of stroke and bleeding vary
according to age. To estimate effects of dabigatran, compared with warfarin, on stroke …
according to age. To estimate effects of dabigatran, compared with warfarin, on stroke …
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation–sub-analysis in Japanese population in RE-LY trial–
M Hori, SJ Connolly, MD Ezekowitz, PA Reilly… - Circulation …, 2011 - jstage.jst.go.jp
Background: RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an
international multicenter study (18,113 patients from 967 centers in 44 countries) that …
international multicenter study (18,113 patients from 967 centers in 44 countries) that …
Dabigatran for anticoagulation in atrial fibrillation–early clinical experience in a hospital population and comparison to trial data
J Michel, D Mundell, T Boga, A Sasse - Heart, Lung and Circulation, 2013 - Elsevier
BACKGROUND: Dabigatran is a recently introduced direct thrombin inhibitor licensed for
use as an oral anticoagulant for stroke prevention in non-valvular atrial fibrillation. Our …
use as an oral anticoagulant for stroke prevention in non-valvular atrial fibrillation. Our …
Dabigatran in real-world atrial fibrillation
J Carmo, FM Costa, J Ferreira… - Thrombosis and …, 2016 - thieme-connect.com
In the RE-LY clinical trial, dabigatran presented a better effectiveness/safety profile when
compared to warfarin. However, clinical trials are not very representative of the real-world …
compared to warfarin. However, clinical trials are not very representative of the real-world …